Trial Profile
A Multicenter, Phase II Trial of Pembrolizumab and Sunitinib in Refractory Advanced Thymic Carcinoma
Status:
Suspended
Phase of Trial:
Phase II
Latest Information Update: 19 Mar 2024
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary) ; Sunitinib (Primary)
- Indications Malignant thymoma
- Focus Therapeutic Use
- 12 Mar 2024 Status changed from recruiting to suspended as per Principal Investigator decision.
- 31 Oct 2023 Planned number of patients changed from 40 to 30.
- 31 Oct 2023 Planned End Date changed from 31 Dec 2023 to 31 Dec 2025.